June 16th 2025
The bkActiv S series is designed to guide nonsurgical urologic, colorectal, and pelvic floor procedures.
Partial nephrectomy shows increased survival benefit
April 15th 2013A recently published population-based study reinforces prior evidence from retrospective studies of the increased survival benefit of partial nephrectomy over radical nephrectomy, and suggests a cancer-specific survival benefit for nephron-sparing approaches as well.
Metastatic renal cell carcinoma agent nearly doubles survival
April 15th 2013A personalized immunotherapy (AGS-003) nearly doubled expected progression-free survival and overall survival when added to standard sunitinib (Sutent) in patients with unfavorable-risk metastatic renal cell carcinoma, according to results from a single-arm phase II study.
Novel VEGF inhibitor may play role in advanced renal cell carcinoma
March 6th 2013Use of tivozanib, an experimental tyrosine kinase inhibitor (TKI) with increased specificity and potency for the vascular endothelial growth factor (VEGF) receptor, as initial targeted therapy for patients with advanced renal cell carcinoma did not translate into improved overall survival compared with sorafenib (Nexavar) in a phase III clinical trial.
Study: Surveillance is safe for small renal masses
February 19th 2013A large retrospective study of older patients diagnosed with small kidney tumors showed that patients who undergo surgery to remove these tumors have the same risk of dying of kidney cancer over a 5-year period as those who undergo surveillance.
Zero-ischemia nephrectomy appears safe, efficacious
February 2nd 2013A technique of zero-ischemia robotic partial nephrectomy (RPN) using near-infrared fluorescence imaging appears to be associated with better postoperative kidney function compared with conventional RPN with main-artery renal clamping.
Thermal ablation common for small renal masses
February 2nd 2013Findings from a recent survey cement the idea that urology departments at academic centers have adopted thermal ablation as an alternative for management of patients with small renal masses, say researchers from the University of Wisconsin, Madison.
Bladder cancer remission improved by adding electromotive mitomycin to BCG
December 31st 2012In patients with stage pT1 urothelial bladder cancer, intravesical bacillus Calmette-Guérin (TheraCys, TICE BCG) combined with electromotive mitomycin-C produces higher remission rates and longer remission times than BCG alone, Italian researchers reported.
Minimally invasive RPLND safe, efficacious in testis cancer
December 31st 2012Minimally invasive retroperitoneal lymph node dissection in testicular cancer reduces length of stay while obtaining a perioperative safety profile comparable to that seen with the open procedure, researchers from the University of California, San Diego Health System reported.